QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials
QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical trials. Today, QPS announced the expansion of its Miami, Florida Phase I clinical trial capabilities to support the growing needs of sponsors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521634782/en/
New, state of the art, clinical trial unit at QPS Miami in South Miami, Florida USA. (Photo: Business Wire)
QPS announces the grand opening of its newest clinical trials unit in Miami, Florida. This new 21 bed unit will complement the existing 85 bed clinical trials unit currently serving the Biotech and Pharmaceutical community. With this new capacity, QPS is poised to accommodate the rapidly increasing demand for obesity trials, as well as continue to support complex, early phase studies in special populations. QPS has extensive experience in allergies, asthma, cell & gene therapy, CNS, COPD, diabetes, elderly, oncology, pediatrics, rheumatoid arthritis, vaccines, women’s health, and many more therapeutic areas.
“We have expanded our Phase I clinical trial capabilities to better serve the hundreds of companies developing potential new obesity-related drugs. We have completed more than 1,500 Phase I-IV clinical trials for drug candidates and this expansion will enable us to support exponentially more sponsors as they progress compounds through proof of concept and First-in-Human trials to the point of candidate nomination,” said Benjamin Chien, Chairman, President, and CEO, QPS Holdings, LLC.
“Our pipeline is filled with sponsors that need this level of support. The number of First-in-Human studies is rapidly increasing and there are very few sites across the country that can conduct them,” said Jose Marcos, Vice President of Clinical Operations, QPS Miami. “QPS is well-known for its success in First-in-Human studies. We excel at complex and special population Phase I trials, and our enrollment and completion rates are among the best in the industry.”
With the expansion comes an increased focus on quality. “To ensure the quality of our clinical trials is maintained, QPS has hired an additional full-time principal investigator to ensure dedicated, physician-involvement at every stage of our trials,” said Chien. “We now have five full-time principal investigators, and a network of more than 25 board-certified subspecialty physician investigators to support the increased volume of studies in our pipeline.”
Wendy Marquina, MD, American Board of Obesity Medicine certified physician, has joined QPS as a primary investigator dedicated to Phase I trials. She brings Board Certification in Obesity, as well as expertise in internal medicine and women’s health to QPS. Since the discovery of the anti-obesity effects of GLP1 and GIP inhibitors, the number of obesity-related clinical trials has dramatically increased. More than 2,300 clinical studies related to obesity are listed as ongoing on clinical trials.gov, and the number is increasing as more companies join the effort to tackle this serious disease and its related comorbidities.
“We expect this demand for obesity-related studies to continue,” said Marquina. “Obesity trials are specialized and unique. And they are in high demand, particularly for companies that want to find an effective solution to this debilitating disease. The road so far is littered with failures in this space, so there is real excitement in the medical community that there may finally be a pathway to help these patients.”
Supporting this expansion in Miami, QPS has co-located its specialty lab services within its Miami-based clinical site. “In the market, you’ll find CROs that offer clinical services, and then you’ll find specialized labs. At QPS, we now we have the unique combination of clinical services and a specialized lab combined under one roof,” said Chien. “That’s important because many of our studies require lab samples to be processed quickly, in less than eight hours. This is only possible by having the clinical site and specialty lab co-located.”
With this newly expanded facility and additional leadership specializing in obesity, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving the needs of the Biotech and Pharmaceutical industry to support global drug development from preclinical through post-marketing needs.
ABOUT QPS HOLDINGS, LLC
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials and clinical research operations services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email infopr@qps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521634782/en/
Contact information
Gabrielle Pastore, QPS
1-302-635-4290
Gabrielle.Pastore@qps.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press Release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
Klarna Partners With Coinbase to Add Stablecoin to Funding Mix19.12.2025 18:00:00 CET | Press Release
Klarna, the global digital bank and flexible payments provider, has partnered with Coinbase to add stablecoin funding to its broad range of traditional sources of funding, which include consumer deposits, long-term loans and short-dated commercial paper. The digital bank plans to raise short-term funding from institutional investors denominated in USDC utilizing Coinbase’s digitally native infrastructure. Adding a USDC-denominated funding source enables Klarna to access USD-like funding directly, tapping into a new pool of institutional investors. “This is an exciting first step into a new way to raise funding,” said Niclas Neglén, Chief Financial Officer, Klarna, “Stablecoin connects us to an entirely new class of institutional investors, and gives us the potential to diversify our funding sources in ways that simply weren't possible a few years ago. This is just the beginning of how digital assets can work alongside our traditional funding sources." Klarna chose Coinbase for this ini
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press Release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press Release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom